Solaris Resources (CVE:SLS) Stock Rating Lowered by Maxim Group

Maxim Group downgraded shares of Solaris Resources (CVE:SLS) from a strong-buy rating to a hold rating in a research report sent to investors on Tuesday morning,Zacks.com reports.

Solaris Resources Price Performance

Shares of SLS opened at C$6.15 on Tuesday. Solaris Resources has a fifty-two week low of C$1.38 and a fifty-two week high of C$7.09. The business has a 50-day moving average of C$6.15 and a 200 day moving average of C$6.15.

About Solaris Resources

SELLAS Life Sciences Group, Inc, a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.